ClinConnect ClinConnect Logo
Search / Trial NCT00000785

A Registry of Tuberculosis Cases in the CPCRA

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Trial Information

Current as of May 09, 2025

Completed

Keywords

Tuberculosis Mycobacterium Tuberculosis Aids Related Opportunistic Infections Acquired Immunodeficiency Syndrome Drug Resistance, Microbial

ClinConnect Summary

Geographic areas and demographic subgroups affected by the TB epidemic appear to be congruent and associated with the concurrent HIV epidemic. The total number of CPCRA patients who will develop, or who have experienced, confirmed TB is unknown. It is critical to determine the depth and breadth of the current problem of drug-resistant TB.

For both retrospective and prospective components of the study, demographic, geographic, HIV and TB risk factor information will be collected on CPCRA patients with confirmed pulmonary or extrapulmonary TB. Mycobacterial culture results will be recorded. ...

Gender

ALL

Eligibility criteria

  • Patients must meet the following criteria:
  • CPCRA patients with confirmed pulmonary or extrapulmonary TB. Confirmed clinical TB requires a positive culture for Mycobacterium tuberculosis.
  • NOTE:
  • There is no requirement that patients have HIV infection.

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

Denver, Colorado, United States

Washington, District Of Columbia, United States

Chicago, Illinois, United States

New Orleans, Louisiana, United States

Detroit, Michigan, United States

Detroit, Michigan, United States

Newark, New Jersey, United States

Bronx, New York, United States

Brooklyn, New York, United States

New York, New York, United States

New York, New York, United States

Richmond, Virginia, United States

Portland, Oregon, United States

Patients applied

0 patients applied

Trial Officials

Fred Gordin

Study Chair

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials